Digital Public Defence: Torleif Tollefsrud Gjølberg
MSc Torleif Tollefsrud Gjølberg at Institute of Clinical Medicine will be defending the thesis “Antibody-based therapeutics for treatment of eye diseases: New insights and tailored procedures” for the degree of PhD (Philosophiae Doctor).
The public defence will be held as a video conference over Zoom.
The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Due to copyright reasons, an electronic copy of the thesis must be ordered from the faculty. In order for the faculty to have time to process the order, it must be received by the faculty no later than 2 days prior to the public defence. Orders received later than 2 days before the defence will not be processed. Inquiries regarding the thesis after the public defence must be addressed to the candidate.
Digital Trial Lecture – time and place
- First opponent: Professor Menna Clatworthy, University of Cambridge, UK
- Second opponent: Associate Professor Vegard Asgeir Forsaa, University of Stavanger
- Third member and chair of the evaluation committee: Associate Professor Susanne Dudman, University of Oslo
Chair of the Defence
Professor Emeritus Frode Vartdal, University of Oslo
Professor Jan Terje Andersen, University of Oslo
Several eye diseases are driven by pathological neovascularization, and are treated by injection of antibody-based therapeutics directed against angiogenic factors directly into the eye. However, recommended injection practices are sub-optimal, and result in drug wastage and a chance of complications for the patient. Furthermore, all available therapeutics bind the same angiogenic molecule, and not all patients respond well to treatment.
In his doctoral thesis, Torleif Tollefsrud Gjølberg together with colleagues tackle various aspects of these problems.
In the clinical setting, they established pharmaceutical compounding of the relevant therapeutics. The resulting procedure is now implemented in several hospitals, where it increases patient safety while reducing both the time spent per patient and associated costs.
In the preclinical setting, they studied how different antibody designs are transported by cells and in animals. The results inform on how therapeutics behave in our bodies, and have implications on how to design future therapeutics.
The researchers also used experimental antibodies in a disease model, and through that revealed a possible new target for therapy. This could pave the way for new treatment, to treat patients who as of today lack options.
Overall, the presented discoveries may lay the foundation for improved treatment of eye diseases.
Contact the research support staff.